Medical Education Library

CLINICAL UPDATE
A Novel TNF Inhibitor for RA: An Update


 

Assessing Cardiovascular Risk in the Patient With Lupus

A supplement to Rheumatology News supported by an unrestricted educational grant from Aspreva Pharmaceuticals. This supplement is based on faculty interviews and is jointly sponsored by The Elsevier Office of Continuing Medical Education (EOCME), an ACCME accredited provider, and Rheumatology News.

• Topic/Faculty
• Target Audience
• Needs Assessment
• Educational Objectives
•Accreditation Statement










To view the supplement, click the image above.

Topic/Faculty

Examining Cardiovascular Risk in Systemic Lupus Erythematosus
Susan Manzi, MD, MPH
Associate Professor of Medicine
Division of Rheumatology and Clinical Immunology
Co-Director of the Lupus Center of Excellence
University of Pittsburgh Medical Center
Dr. Manzi has nothing to disclose.

Managing Cardiovascular Risk in Systemic Lupus Erythematosus
Daniel Edmundowicz, MD
Associate Professor of Medicine
Director, Preventive Cardiology
University of Pittsburgh Medical Center
Dr. Edmundowicz has no financial relationships to report. He discusses the off-label/investigational uses of commercial products.

Target Audience

The following educational activity is for primary care physicians and rheumatologists who provide care for patients with systemic lupus erythematosus.

Needs Assessment

As diagnosis and management of systemic lupus erythematosus (SLE) have improved, patient survival has increased substantially. In the process, the focus of care has shifted toward management of long-term consequences of the disease. In particular, cardiovascular disease (CVD) has emerged as a major source of morbidity and mortality among patients with SLE. Not uncommonly, SLE is associated with multiple CVD risk factors, resulting in a pathologic collaboration that greatly increases the risk of atherosclerosis and myocardial infarction in patients with SLE. The onus is on physicians to monitor CVD risk closely in patients with SLE to improve the chances of early recognition and afford the opportunity for aggressive intervention to keep risk factors at bay.

Educational Objectives

After completing this educational activity, participants should be able to:

• Understand and appreciate the increased CVD risk faced by patients with SLE.

• Identify CVD risk factors that can be minimized by intervention.

• Recognize the need for ongoing clinical vigilance, early recognition, and aggressive treatment of CVD risk factors.

• Identify therapies that can help reduce the CVD risk in patients with SLE.

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and Rheumatology News. The EOCME is accredited by the ACCME to provide continuing medical education (CME) for physicians.

The EOCME designates this educational activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Term of Approval: May 2007-May 31, 2008.

Copyright © 2007 Elsevier Inc.

Recommended for You

News & Commentary

Quizzes from MD-IQ

Research Summaries from ClinicalEdge